KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Debt (2016 - 2020)

Nektar Therapeutics has reported Total Debt over the past 10 years, most recently at $508.9 million for Q1 2020.

  • Quarterly results put Total Debt at $508.9 million for Q1 2020, up 105.73% from a year ago — trailing twelve months through Mar 2020 was $508.9 million (up 105.73% YoY), and the annual figure for FY2019 was $252.9 million, up 2.41%.
  • Total Debt for Q1 2020 was $508.9 million at Nektar Therapeutics, up from $252.9 million in the prior quarter.
  • Over the last five years, Total Debt for NKTR hit a ceiling of $508.9 million in Q1 2020 and a floor of $242.1 million in Q1 2016.
  • Median Total Debt over the past 5 years was $245.6 million (2018), compared with a mean of $261.2 million.
  • Biggest five-year swings in Total Debt: rose 0.71% in 2019 and later soared 105.73% in 2020.
  • Nektar Therapeutics' Total Debt stood at $243.5 million in 2016, then increased by 0.72% to $245.2 million in 2017, then increased by 0.71% to $247.0 million in 2018, then rose by 2.41% to $252.9 million in 2019, then skyrocketed by 101.25% to $508.9 million in 2020.
  • The last three reported values for Total Debt were $508.9 million (Q1 2020), $252.9 million (Q4 2019), and $248.3 million (Q3 2019) per Business Quant data.